Your browser doesn't support javascript.
loading
Expanding the horizon of research into the pathogenesis of the white matter diseases: Proceedings of the 2021 Annual Workshop of the Albert Research Institute for White Matter and Cognition.
Whitehead, Shawn N; Bruno, Askiel; Burns, Jeffrey M; Carmichael, S Thomas; Csiszar, Anna; Edwards, Jodi D; Elahi, Fanny M; Faraco, Giuseppe; Gould, Douglas B; Gustafson, Deborah R; Hachinski, Vladimir; Rosenberg, Gary; Sorond, Farzaneh A; Shih, Andy Y; Tse, Kai Hei; Ungvari, Zoltan; Wilcock, Donna M; Zuloaga, Kristen L; Barone, Frank C.
Afiliación
  • Whitehead SN; Department of Anatomy and Cell Biology, Western University, London, ON, N6A 3K7, Canada. shawn.whitehead@schulich.uwo.ca.
  • Bruno A; Department of Neurology, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA.
  • Burns JM; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Carmichael ST; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
  • Csiszar A; Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
  • Edwards JD; International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Elahi FM; University of Ottawa Heart Institute, Ottawa, Canada.
  • Faraco G; School of Epidemiology and Public Health, University of Ottawa, Ottawa, K1G 5Z3, Canada.
  • Gould DB; Memory and Aging Center, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, 94158, USA.
  • Gustafson DR; Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, 10065, USA.
  • Hachinski V; Departments of Ophthalmology and Anatomy, and Institute for Human Genetics, School of Medicine, University of California, San Francisco, 94143, USA.
  • Rosenberg G; Department of Neurology, Section for NeuroEpidemiology, State University of New York Downstate Health Sciences University, New York, Brooklyn, 11203, USA.
  • Sorond FA; Department of Clinical Neurological Sciences, Western University, London, ON, N6A 5C1, Canada.
  • Shih AY; UNM Health Sciences Center, University of New Mexico, Albuquerque, NM, 87106, USA.
  • Tse KH; Department of Neurology, Northwestern University, Chicago, IL, USA.
  • Ungvari Z; Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute; Department of Pediatrics; Department of Bioengineering, University of Washington, Seattle, WA, USA.
  • Wilcock DM; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
  • Zuloaga KL; Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
  • Barone FC; International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Translational Medicine, Semmelweis University, Budapest, Hungary.
Geroscience ; 44(1): 25-37, 2022 02.
Article en En | MEDLINE | ID: mdl-34606040
ABSTRACT
White matter pathologies are critically involved in the etiology of vascular cognitive impairment-dementia (VCID), Alzheimer's disease (AD), and Alzheimer's disease and related diseases (ADRD), and therefore need to be considered a treatable target ( Roseborough A, Hachinski V, Whitehead S. White matter degeneration - a treatable target? Roseborough et al. JAMA Neurol [Internet]. 2020 Apr 27;77(7)793-4, [1] . To help address this often-missed area of research, several workshops have been sponsored by the Leo and Anne Albert Charitable Trust since 2015, resulting in the incorporation of "The Albert Research Institute for White Matter and Cognition" in 2020. The first annual "Institute" meeting was held virtually on March 3-4, 2021. The Institute provides a forum and workspace for communication and support of the advancement of white matter science and research to better understand the evolution and prevention of dementia. It serves as a platform for young investigator development, to introduce new data and debate biology mechanisms and new ideas, and to encourage and support new research collaborations and directions to clarify how white matter changes, with other genetic and health risk factors, contribute to cognitive impairment. Similar to previous Albert Trust-sponsored workshops (Barone et al. in J Transl Med 141-14, [2]; Sorond et al. in GeroScience 4281-96, [3]), established expert investigators were identified and invited to present. Opportunities to attend and present were also extended by invitation to talented research fellows and younger scientists. Also, updates on institute-funded research collaborations were provided and discussed. The summary that follows is a synopsis of topics and discussion covered in the workshop.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Demencia Vascular / Leucoencefalopatías / Sustancia Blanca Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Geroscience Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Demencia Vascular / Leucoencefalopatías / Sustancia Blanca Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Geroscience Año: 2022 Tipo del documento: Article País de afiliación: Canadá